-
EP4275677
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4275677
| EP4275677 - DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND [Right-click to bookmark this link] | Status | The application has been published Status updated on 13.10.2023 Database last updated on 08.06.2024 | Most recent event Tooltip | 08.12.2023 | Publication of search report | published on 10.01.2024 [2024/02] | 08.12.2023 | Change - classification | published on 10.01.2024 [2024/02] | 08.12.2023 | Change - classification | published on 10.01.2024 [2024/02] | Applicant(s) | For all designated states Ascendis Pharma Bone Diseases A/S Tuborg Boulevard 12 2900 Hellerup / DK | [2023/46] | Inventor(s) | 01 /
Holten-Andersen, Lars 2900 Hellerup / DK | 02 /
Sprogøe, Kennett 2900 Hellerup / DK | 03 /
Karpf, David Brian Palo Alto, 94304 / US | [2023/46] | Representative(s) | Büchel, Edwin Patentanwälte Isenbruck Bösl Hörschler PartG mbB Eastsite One Seckenheimer Landstraße 4 68163 Mannheim / DE | [2023/46] | Application number, filing date | 23185728.5 | 28.09.2017 | [2023/46] | Priority number, date | EP20160191451 | 29.09.2016 Original published format: EP 16191451 | EP20170155843 | 13.02.2017 Original published format: EP 17155843 | [2023/46] | Previously filed application, date | WO2017EP74592 | 28.09.2017 | [2023/46] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP4275677 | Date: | 15.11.2023 | Language: | EN | [2023/46] | Type: | A3 Search report | No.: | EP4275677 | Date: | 10.01.2024 | Language: | EN | [2024/02] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 11.12.2023 | Classification | IPC: | A61K38/29, A61K9/00, A61K47/34, A61K9/16, A61P5/18, A61P7/00, A61P7/04, A61P17/14, A61P19/02, A61P19/08, A61P29/00, A61P19/10 | [2024/02] | CPC: |
A61K38/29 (EP,IL,KR,US);
A61K47/34 (EP,IL,KR,US);
A61K47/54 (US);
A61K47/545 (US);
A61K47/60 (US);
A61K9/0019 (KR,US);
A61K9/1647 (EP,IL,KR,US);
A61P17/14 (EP);
A61P19/02 (EP);
A61P19/08 (EP);
A61P19/10 (EP);
A61P29/00 (EP);
|
| Former IPC [2023/46] | A61K9/16 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/46] | Validation states | MA | Not yet paid | Title | German: | DOSIERSCHEMA ZUR KONTROLLIERTEN FREISETZUNG EINER PTH-VERBINDUNG | [2023/46] | English: | DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND | [2023/46] | French: | SCHÉMA POSOLOGIQUE POUR COMPOSÉ PTH À LIBÉRATION CONTROLÉE | [2023/46] | Parent application(s) Tooltip | EP17781425.8 / EP3518960 | Fees paid | Renewal fee | 17.07.2023 | Renewal fee patent year 03 | 17.07.2023 | Renewal fee patent year 04 | 17.07.2023 | Renewal fee patent year 05 | 17.07.2023 | Renewal fee patent year 06 | 17.07.2023 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2011012721 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * the whole document *; | [A]WO2011012723 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * the whole document *; | [A]WO2011012719 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * the whole document *; | [A]WO2011042450 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * the whole document *; | [A]WO2011089214 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * page 19, line 9 * * claims 1-15 *; | [A]WO2011089215 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * the whole document *; | [A]WO2011089216 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * the whole document *; | [A]WO2013024049 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * page 106, line 12 * * claims 1-20 *; | [A]WO2013024053 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * page 63, line 12 * * claims 1-13 *; | [A]WO2013024051 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * the whole document *; | [A]WO2013053856 (ASCENDIS PHARMA AS [DK], et al) [A] 1-15 * the whole document *; | [A]WO2014056926 (ASCENDIS PHARMA AS [DK]) [A] 1-15 * page 28, line 39 * * claims 1-35 *; | [A]WO2014056923 (ASCENDIS PHARMA OPHTHALMOLOGY DIVISION AS [DK]) [A] 1-15 * the whole document *; | [A]WO2014056915 (ASCENDIS PHARMA AS [DK]) [A] 1-15 * the whole document *; | [A]WO2014086961 (ASCENDIS PHARMA AS [DK]) [A] 1-15 * the whole document *; | [A]WO2014173759 (ASCENDIS PHARMA AS [DK]) [A] 1-15 * page 150, line 10 * * claims 1-23 *; | [A]WO2015052155 (ASCENDIS PHARMA AS [DK]) [A] 1-15 * the whole document *; | [A]WO2016020373 (ASCENDIS PHARMA AS [DK]) [A] 1-15 * the whole document *; | [A]WO2016110577 (ASCENDIS PHARMA AS [DK]) [A] 1-15 * the whole document *; | [A] - WEI G ET AL, "The release profiles and bioactivity of parathyroid hormone from poly(lactic-co-glycolic acid) microspheres", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, (20040101), vol. 25, no. 2, doi:10.1016/S0142-9612(03)00528-3, ISSN 0142-9612, pages 345 - 352, XP004469625 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/S0142-9612(03)00528-3 | by applicant | EP1536334 | WO29095479 | WO02089789 | WO2005027978 | WO2005099768 | WO2006003014 | WO2006136586 | WO2008034122 | WO2008155134 | WO2009009712 | WO2009095479 | US7585837 | WO2009143412 | WO2010091122 | WO2011012722 | WO2011012715 | WO2011082368 | WO2011089216 | WO2011089214 | WO2011089215 | WO2011123813 | WO2011144756 | WO2012002047 | US2012035101 | WO2013024053 | WO2013024052 | WO2013024049 | WO2013024048 | WO2013036857 | WO2013160340 | US8618124 | WO2014056926 | WO2014060512 | US8754190 | US8946405 | WO2016020373 | - BOWIE et al., Science, (19900000), vol. 247, pages 1306 - 1310 | - WATCHOM, Biochem J, (19330000), vol. 27, no. 6, pages 1875 - 1878 |